(Q37355664)

English

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia

scientific article published on 03 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia (English)

1 reference

Europe PubMed Central

19 August 2017

phase I clinical trial

0 references

apoptotic process

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Aaron D Schimmer

1

0 references

object named as

David W Hedley

10

0 references

Gautam Borthakur

3

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

19 August 2017

Michael Andreeff

18

object named as

Michael Andreeff

1 reference

Europe PubMed Central

19 August 2017

Martin S. Tallman

6

object named as

Martin S Tallman

1 reference

Europe PubMed Central

19 August 2017

2

object named as

Elihu H Estey

1 reference

Europe PubMed Central

19 August 2017

author name string

Bing Z Carter

4

1 reference

Europe PubMed Central

19 August 2017

Gary J Schiller

5

1 reference

Europe PubMed Central

19 August 2017

Jessica K Altman

7

1 reference

Europe PubMed Central

19 August 2017

Judith E Karp

8

1 reference

Europe PubMed Central

19 August 2017

Jeannine Kassis

9

1 reference

Europe PubMed Central

19 August 2017

Joseph Brandwein

11

1 reference

Europe PubMed Central

19 August 2017

Wei Xu

12

1 reference

Europe PubMed Central

19 August 2017

Duncan H Mak

13

1 reference

Europe PubMed Central

19 August 2017

Eric LaCasse

14

1 reference

Europe PubMed Central

19 August 2017

Christine Jacob

15

1 reference

Europe PubMed Central

19 August 2017

Stephen J Morris

16

1 reference

Europe PubMed Central

19 August 2017

Jacques Jolivet

17

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

3 August 2009

1 reference

Europe PubMed Central

19 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

19 August 2017

27

1 reference

Europe PubMed Central

19 August 2017

28

1 reference

Europe PubMed Central

19 August 2017

4741-4746

1 reference

Europe PubMed Central

19 August 2017

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Mechanism of XIAP-mediated inhibition of caspase-9

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Structural basis for the inhibition of caspase-3 by XIAP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

X-linked IAP is a direct inhibitor of cell-death proteases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

6 September 2017

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

14 September 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

14 September 2017

Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

2 September 2018

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

2 September 2018

Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5073380

2 September 2018

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19652057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19652057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19652057

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.21.8172

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37355664&oldid=1810099279"